Genzyme Belgium Genzyme Corporate Search Contact us
HealthcarePatients & FamiliesPractical Info
A disease with many faces
 
Healthcare Professionals
About Lysosomal Storage Disease
History
Biology of the lysosome
Lysosomes and disease
Molecular pathogenesis
Disease progression
Presentation & progression
Disease management
Diagnosis & testing
Genetics
Summary of Product Characteristics
Gaucher
Fabry
MPS I
Pompe

 



 

About Lysosomal Storage Disorders

All lysosomal storage disorders share a common pathogenesis: a genetic defect in a specific lysosomal enzyme, receptor target, activator protein, membrane protein, or transporter, leading to accumulation of substrates in cell lysosomes.[1] The clinical manifestations, however, are widely varying across the LSD category and sometimes even within a particular disease, depending on the genetic defect and the particular substrate stored.

To view detailed clinical fact sheets on each of the 40+ diseases visit www.lysosomallearning.com

References

1.Wilcox, WR. Lysosomal Storage Disorders: The Need for Better Pediatric Recognition and Comprehensive Care. Journal of Pediatrics; May 2004: S3-S14.

 
Print

PRINT

Bookmark

BOOKMARK




01/01/2007: Low bone density in Gaucher disease improves with CerezymeŽ

01/05/2007: Treatment for Pompe disease now available for Belgian patients

01/03/2006: Early treatment with FabrazymeŽ significantly slows progression of Fabry

More >



Lysosomal Storage Disorders
General information
Gaucher Disease
Fabry Disease
MPS I Disease
Pompe Disease